| Name | Title | Contact Details |
|---|
Spyryx Biosciences was formed in 2013 by our scientific founder, Dr. Robert Tarran, based on his discovery of a previously unknown mechanism that the lung uses to regulate fluid on its surface. This mechanism is dysfunctional in the lungs of CF patients due to genetic mutations and is believed to be the root cause of the progressive dehydration that leads to the unfortunate cycle of mucus accumulation, bacterial colonization, immune response and tissue scarring, loss of lung function, and often early death.
Seagull Environmental Tech is a Overland Park, KS-based company in the Business Services sector.
We are industry leaders in supplying, selling, and servicing air content (flights, ancillaries, bundles, brands) for the travel supply chain. Founded in 2009, Mystifly has earned a reputation for applying the right mix of technology and innovative thought to create B2B solutions that deliver value and exceed customer expectations. As a result, Mystifly is trusted by over 700 airlines and 3000+ travel sellers worldwide. The Mystifly Smart Selling Platform (SSP) is an iPaaS solution purpose-built for sourcing, selling, and servicing air travel in any channel (direct or indirect). Using SSP, airlines and travel sellers can deliver superior travel offerings and experiences for their customers without the headaches of managing multiple APIs, air sources, servicing challenges, or complex/delayed payment and settlement. The system aggregates, normalises, and optimises global air content – 700+ NDC, GDS, and LCC airlines – and provides a cloud-based solution for selling air at scale in support of the entire Offer-Order-Settle-Deliver (OOSD) lifecycle.
Spot 4 Kids Inc is a Oswego, IL-based company in the Business Services sector.
DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors. We have deployed more than $2.5 billion, acquiring more than 70 royalties on 40-plus drugs.